Artiva Biotherapeutics (ARTV) Accumulated Expenses (2023 - 2025)
Historic Accumulated Expenses for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $7.0 million.
- Artiva Biotherapeutics' Accumulated Expenses fell 1579.58% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 1579.58%. This contributed to the annual value of $7.4 million for FY2024, which is 779.59% down from last year.
- Latest data reveals that Artiva Biotherapeutics reported Accumulated Expenses of $7.0 million as of Q3 2025, which was down 1579.58% from $5.8 million recorded in Q2 2025.
- In the past 5 years, Artiva Biotherapeutics' Accumulated Expenses ranged from a high of $8.3 million in Q3 2024 and a low of $5.8 million during Q2 2025
- In the last 3 years, Artiva Biotherapeutics' Accumulated Expenses had a median value of $7.0 million in 2025 and averaged $7.0 million.
- Examining YoY changes over the last 5 years, Artiva Biotherapeutics' Accumulated Expenses showed a top increase of 605.09% in 2025 and a maximum decrease of 1579.58% in 2025.
- Artiva Biotherapeutics' Accumulated Expenses (Quarter) stood at $8.0 million in 2023, then fell by 7.8% to $7.4 million in 2024, then dropped by 4.95% to $7.0 million in 2025.
- Its last three reported values are $7.0 million in Q3 2025, $5.8 million for Q2 2025, and $6.4 million during Q1 2025.